Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines

References

• Bestor TH, Chandler VL, Feinberg AP. Epigenetic effects in eukaryotic gene expression. Dev Genet 1994;15:458–462.
   PubMedGoogle Scholar
• Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457–463.
   PubMed Web of Science ®Google Scholar
• Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003;22:6489–6496.
   PubMed Web of Science ®Google Scholar
• Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006;20:1–13.
   PubMed Web of Science ®Google Scholar
• Petti MC, Mandelli F, Zagonel V, et al Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993;7(Suppl 1):36–41.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Assouline S, Cortes J, et al Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112:981–989.
   PubMed Web of Science ®Google Scholar
• Qin T, Youssef EM, Jelinek J, et al Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 2007;13:4225–4232.
   PubMed Web of Science ®Google Scholar
• Zhu J, Koken MH, Quignon F, et al Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:3978–3983.
   PubMed Web of Science ®Google Scholar
• Bonati A, Rizzoli V, Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 2006;7:397–405.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Shi XG, Tang W, et al Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345–3353.
   PubMed Web of Science ®Google Scholar
• Aposhian HV. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Ann Rev Pharmacol Toxicol 1997;37:397–419.
   PubMed Web of Science ®Google Scholar
• Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene P53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997;386:263–277.
   PubMed Web of Science ®Google Scholar
• Chai CY, Huang YC, Hung WC, Kang WY, Chen WT. Arsenic salts induced autophagic cell death and hypermethylation of DAPK promoter in SV-40 immortalized human uroepithelial cells. Toxicol Lett 2007;173:48–56.
   PubMed Web of Science ®Google Scholar
• Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, Hirano S. Arsenic trioxide inhibits DNA methyltransferase and restores methylation- silenced genes in human liver cancer cells. Hum Pathol 2006;37:298–311.
   PubMed Web of Science ®Google Scholar
• Ramirez T, Brocher J, Stopper H, Hock R. Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells. Chromosoma 2008;117:147–157.
   PubMed Web of Science ®Google Scholar
• Zhou X, Sun H, Ellen TP, Chen H, Costa M. Arsenite alters global histone H3 methylation. Carcinogenesis 2008;29:1831–1836.
   PubMed Web of Science ®Google Scholar
• Chen G, Wang Y, Huang H, et al Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol 2009;82:176–183.
   PubMed Web of Science ®Google Scholar
• Fraga MF, Rodriquez R, Canal MJ. Rapid quantification of DNA methylation by high performance capillary electrophoresis. Electrophoresis 2000;21:2990–2994.
   PubMed Web of Science ®Google Scholar
• Van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002;16:1362–1371.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
   PubMedGoogle Scholar
• Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517–1524.
   PubMed Web of Science ®Google Scholar
• Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739–749.
   PubMed Web of Science ®Google Scholar
• Sciandrello G, Caradonna F, Mauro M, Barbata G. Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells. Carcinogenesis 2004;25:413–417.
   PubMed Web of Science ®Google Scholar
• Reichard JF, Schnekenburger M, Puga A. Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem Biophys Res Commun 2007;352:188–192.
   PubMed Web of Science ®Google Scholar
• Okoji RS, Yu RC, Maronpot RR, Froines JR. Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. Carcinogenesis 2002;23:777–785.
   PubMed Web of Science ®Google Scholar
• Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 2001;175:260–268.
   PubMed Web of Science ®Google Scholar
• Tong H, Lin M. Arsenic trioxide induced p15INK4B gene expression in myelodysplastic syndrome cell line MUTZ-1. Chinese J Hematol 2002;23:638–641.
   Google Scholar
• Fu HY, Sheng JZ, Sheng SF, Zhou HR. n-MSP detection of p16 gene demethylation and transcription in human multiple myeloma U266 cell line induced by arsenic trioxide. J Exp Hematol 2007;15:79–85.
   Google Scholar
• Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 1980;56:344–350.
   PubMed Web of Science ®Google Scholar
• Hellebreker DM, Griffioen AW, van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta 2007;1775:76–91.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174–17179.
   PubMed Web of Science ®Google Scholar
• Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL specifictyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001;15:342–347.
   PubMed Web of Science ®Google Scholar
• Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145–154.
   PubMed Web of Science ®Google Scholar
• Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission. Oncogene 2001;20:7257–7265.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271–3279.
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005;4:1993–2000.
   PubMed Web of Science ®Google Scholar
• Carraway HE, Gore SD. Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol 2007;25:1955–1956.
   PubMed Web of Science ®Google Scholar